Propel Bio Management, LLC Athira Pharma, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q3 2024
A detailed history of Propel Bio Management, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 1,492,792 shares of ATHA stock, worth $970,314. This represents 0.39% of its overall portfolio holdings.
Number of Shares
1,492,792
Previous 1,492,792
-0.0%
Holding current value
$970,314
Previous $3.96 Billion
83.17%
% of portfolio
0.39%
Previous 2.57%
Shares
1 transactions
Others Institutions Holding ATHA
# of Institutions
66Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$3.51 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$1.05 Million0.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$970,3140.04% of portfolio
-
Black Rock Inc. New York, NY676KShares$439,5580.0% of portfolio
-
Tang Capital Management LLC San Diego, CA600KShares$390,0000.02% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $24.6M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...